RxDoctor Payments Data

John Harris, MD

Infectious Disease · Burbank, CANPI 1356648703

Payments from drug & device makers

$1,409in general payments, 2019–2025

Across 79 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$487
  • Johnson & Johnson$263
  • Viiv Healthcare Company$236
  • Philips North America LLC$133
  • Insmed, Inc.$100
  • Janssen Products, LP$72
  • plus $119 from 3 others

What the payments were for

  • Food & beverage$1,28991%
  • Education$1219%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,409 in reported general payments places this provider in the 60th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$211,505
Medicare patients
370
Services billed
1,783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala82$434,752
GenvoyaElviteg/Cob/Emtri/Tenof Alafen48$222,602
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf29$168,006
TriumeqAbacavir/Dolutegravir/Lamivudi21$79,703
TivicayDolutegravir Sodium29$78,869
OdefseyEmtricitab/Rilpiviri/Tenof Ala24$77,826
DovatoDolutegravir Sodium/Lamivudine23$67,418
Maraviroc13$32,106
DescovyEmtricitabine/Tenofov Alafenam14$30,940
IsentressRaltegravir Potassium13$26,098
ErtapenemErtapenem Sodium15$11,613
Etravirine12$8,688
Daptomycin17$4,537
CeftriaxoneCeftriaxone Sodium38$1,774
Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod11$519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$487$688,294144 claims
Viiv Healthcare CompanyTriumeq, Tivicay, Dovato$236$225,99073 claims
Janssen Products, LPSymtuza$72$168,00629 claims
MerckIsentress$62$26,09813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 856 infectious disease providers in California.

Other infectious disease in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →